Published in Int J Cardiovasc Imaging on August 21, 2011
Stent evaluation with optical coherence tomography. Yonsei Med J (2013) 0.92
OCT demonstrating neoatherosclerosis as part of the continuous process of coronary artery disease. Herz (2015) 0.75
Should we rely on OCT to assess the improvements of new generation drug-eluting stents? Int J Cardiovasc Imaging (2011) 0.75
Cardiovascular imaging 2012 in the International Journal of Cardiovascular Imaging. Int J Cardiovasc Imaging (2013) 0.75
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med (2004) 11.86
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA (2005) 9.81
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation (2007) 5.05
Assessment of coronary arterial thrombus by optical coherence tomography. Am J Cardiol (2006) 1.89
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med (2010) 1.70
Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv (2009) 1.70
Optical coherence evaluation of everolimus-eluting stents 8 months after implantation. Heart (2010) 1.54
Short- and mid-term intravascular ultrasound analysis of the new zotarolimus-eluting stent with durable polymer – results from the RESOLUTE trial –. Circ J (2010) 1.41
Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. Am J Cardiol (2007) 1.40
Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents. Heart (2009) 1.31
Intravascular optical coherence tomography: optimisation of image acquisition and quantitative assessment of stent strut apposition. EuroIntervention (2007) 1.07
Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial. JACC Cardiovasc Interv (2009) 1.07
Comparison of neointimal coverage of sirolimus-eluting stents and paclitaxel-eluting stents using optical coherence tomography at 9 months after implantation. Circ J (2009) 0.98
The initial extent of malapposition in ST-elevation myocardial infarction treated with drug-eluting stent: the usefulness of optical coherence tomography. Yonsei Med J (2010) 0.96
The next generation Endeavor Resolute Stent: role of the BioLinx Polymer System. EuroIntervention (2007) 0.87
Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. Am Heart J (2007) 0.87
Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation: comparison with sirolimus-eluting stent using optical coherence tomography. Int J Cardiovasc Imaging (2011) 0.86
Intracoronary thrombus formation after drug-eluting stents implantation: optical coherence tomographic study. Am Heart J (2010) 0.83
Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc Interv (2009) 0.76
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med (2008) 4.96
Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med (2011) 3.55
Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis. Circ Cardiovasc Interv (2009) 3.36
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation (2011) 2.40
Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation (2011) 2.34
The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. Int J Cardiol (2008) 2.31
A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol (2012) 2.28
Sex differences in central hemodynamics and their relationship to left ventricular diastolic function. J Am Coll Cardiol (2011) 2.13
A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med (2003) 2.07
Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care (2004) 1.84
Prognostic value of longitudinal strain after primary reperfusion therapy in patients with anterior-wall acute myocardial infarction. J Am Soc Echocardiogr (2007) 1.74
Adiponectin concentrations: a genome-wide association study. Am J Hum Genet (2010) 1.70
Effectiveness and safety of endovascular aneurysm treatment in patients with vasculo-Behçet disease. J Endovasc Ther (2009) 1.66
Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv (2010) 1.65
Reactive oxygen species inhibit adhesion of mesenchymal stem cells implanted into ischemic myocardium via interference of focal adhesion complex. Stem Cells (2010) 1.63
Incidences, predictors, and clinical outcomes of acute and late stent malapposition detected by optical coherence tomography after drug-eluting stent implantation. Circ Cardiovasc Interv (2014) 1.62
Effects of lycopene supplementation on oxidative stress and markers of endothelial function in healthy men. Atherosclerosis (2010) 1.61
Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol (2005) 1.59
Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry. Eur Heart J (2008) 1.58
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J (2010) 1.57
Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation. Int J Cardiol (2007) 1.56
Mitral valve repair versus revascularization alone in the treatment of ischemic mitral regurgitation. Circulation (2006) 1.54
Relationship between multiple plasma biomarkers and vulnerable plaque determined by virtual histology intravascular ultrasound. Circ J (2009) 1.53
Final kissing ballooning and long-term clinical outcomes in coronary bifurcation lesions treated with 1-stent technique: results from the COBIS registry. Heart (2011) 1.52
Antiarrhythmic potential of mesenchymal stem cell is modulated by hypoxic environment. J Am Coll Cardiol (2012) 1.52
Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol (2006) 1.52
Cordycepin inhibits lipopolysaccharide-induced inflammation by the suppression of NF-kappaB through Akt and p38 inhibition in RAW 264.7 macrophage cells. Eur J Pharmacol (2006) 1.51
Left atrial volume index: a predictor of adverse outcome in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr (2009) 1.50
Randomised comparison of strut coverage between Nobori biolimus-eluting and sirolimus-eluting stents: an optical coherence tomography analysis. EuroIntervention (2014) 1.47
Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents. Catheter Cardiovasc Interv (2008) 1.47
Identification of a glutamic acid repeat polymorphism of ALMS1 as a novel genetic risk marker for early-onset myocardial infarction by genome-wide linkage analysis. Circ Cardiovasc Genet (2013) 1.47
Abnormal longitudinal myocardial functional reserve assessed by exercise tissue Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr (2006) 1.47
Outcomes of endovascular management for complicated chronic type B aortic dissection: effect of the extent of stent graft coverage and anatomic properties of aortic dissection. J Vasc Interv Radiol (2013) 1.47
Is prophylactic aortic valve replacement indicated during mitral valve surgery for mild to moderate aortic valve disease? Ann Thorac Surg (2002) 1.47
A genome-wide association study of a coronary artery disease risk variant. J Hum Genet (2013) 1.46
Comparison of cilostazol and clopidogrel after successful coronary stenting. Am J Cardiol (2005) 1.45
Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol (2005) 1.45
Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia. J Cardiovasc Pharmacol Ther (2011) 1.43
Small-diameter blood vessels engineered with bone marrow-derived cells. Ann Surg (2005) 1.43
Anatomic and functional evaluation of bifurcation lesions undergoing percutaneous coronary intervention. Circ Cardiovasc Interv (2010) 1.42
Comparison of plain balloon and cutting balloon angioplasty for the treatment of restenosis with drug-eluting stents vs bare metal stents. Circ J (2010) 1.42
Metabolic profiling of plasma in overweight/obese and lean men using ultra performance liquid chromatography and Q-TOF mass spectrometry (UPLC-Q-TOF MS). J Proteome Res (2010) 1.42
Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients: the Korean Multicenter Angioplasty Team (KOMATE) Registry. Catheter Cardiovasc Interv (2008) 1.42
Impact of the extent of coronary artery disease on outcomes after revascularization for unprotected left main coronary artery stenosis. J Am Coll Cardiol (2010) 1.41
Soluble fms-like tyrosine kinase-1 and the progression of carotid intima-media thickness – 24-month follow-up study –. Circ J (2010) 1.41
Comparison between sirolimus- and Paclitaxel-eluting stents for the treatment of chronic total occlusions. J Invasive Cardiol (2006) 1.41
Optical coherence tomography-based predictors for creatine kinase-myocardial band elevation after elective percutaneous coronary intervention for in-stent restenosis. Catheter Cardiovasc Interv (2014) 1.41
Heterogeneous effects of association between blood pressure loci and coronary artery disease in east Asian individuals. Circ J (2015) 1.39
Two cases of subintimal angioplasty with proximal stent implantation for long superficial femoral artery occlusions. Catheter Cardiovasc Interv (2005) 1.39
Coupling bifurcated stent-grafts to overcome anatomic limitations of endovascular repair of abdominal aortic aneurysms. J Vasc Interv Radiol (2012) 1.39
Early and late clinical outcomes after rotational atherectomy with stenting versus rotational atherectomy with balloon angioplasty for complex coronary lesions. J Invasive Cardiol (2004) 1.39
Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension (2013) 1.32